Skip to main content
. Author manuscript; available in PMC: 2017 Jul 18.
Published in final edited form as: Pediatr Res. 2017 Jan 18;81(6):865–872. doi: 10.1038/pr.2017.15

Table 1.

Clinical Characteristics of Neonates with HIE Who Received Hypothermia and High-Dose Epo

Phase I Study (n=24) Phase II Study (n=24)
Gestational Age at Birth (completed), wks 39 (36 – 42) 39 (36 – 41)
Birthweight, kg 3.47 (1.92 – 4.08) 3.39 (2.68 – 4.71)
Female, n (%) 12 (50%) 14 (58%)
APGAR
 5 min 3 (0 – 8) 3 (0 – 7)
 10 min 4 (0 – 8) 5 (1 – 8)
First arterial or capillary pH 6.90 (6.72 – 7.23) 6.91 (6.70 – 7.29)
Base Deficit, mmol/L −16 (−27 – −10) −17 (−33 – −2)
Crmax, mg/dL 0.9 (0.6 – 2.8) 1.0 (0.6 – 3.5)
Crmax >1.4 mg/dL, n (%) 1 (4%) 5 (21%)
ALTmax, U/L 65 (13 – 692) 62 (14 – 926)
ALTmax >100 U/L, n (%) 8 (33%) 10 (42%)
Intubation >12h, n (%) 16 (67%) 17 (71%)
Clinical Seizure, n (%) 9 (38%) 8 (33%)
Hypotension requiring inotrope, n (%) 10 (42%) 9 (38%)
Death during hospitalization, n (%) 0 (0%) 2 (8%)

All data are median (range) or number of patients (%). Crmax, maximum serum creatinine during study period; ALTmax, maximum alanine aminotransferse during study period.